S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

bioMérieux Stock Forecast, Price & News

0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $140.26
50-Day Range
MA: $141.83
52-Week Range
Now: $140.26
Average Volume201 shs
Market Capitalization$16.60 billion
P/E Ratio54.36
Dividend YieldN/A
bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
bioMérieux logo


Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Private households



Sales & Book Value

Annual Sales$3.00 billion
Cash Flow$4.37 per share
Book Value$21.33 per share



Market Cap$16.60 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableNot Optionable
0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMXMF News and Ratings via Email

Sign-up to receive the latest news and ratings for BMXMF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

bioMérieux (OTCMKTS:BMXMF) Frequently Asked Questions

How has bioMérieux's stock been impacted by Coronavirus?

bioMérieux's stock was trading at $91.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BMXMF shares have increased by 53.3% and is now trading at $140.26.
View which stocks have been most impacted by COVID-19

Is bioMérieux a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last year. There are currently 2 sell ratings, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" bioMérieux stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMXMF, but not buy additional shares or sell existing shares.
View analyst ratings for bioMérieux
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than bioMérieux?

Wall Street analysts have given bioMérieux a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but bioMérieux wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is bioMérieux's next earnings date?

bioMérieux is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for bioMérieux

Who are some of bioMérieux's key competitors?

Who are bioMérieux's key executives?

bioMérieux's management team includes the following people:
  • Mr. Alexandre Mérieux, Chairman & CEO (Age 47)
  • Mr. Frédéric Besème, Employee Director & Head of CSR (Age 65)
  • Mr. Guillaume Bouhours, Exec. VP of Purchasing and Information Systems & CFO (Age 45)
  • Mr. Pierre Boulud, Exec. VP of Clinical Operations & COO (Age 50)
  • Sylvain Morgeau, Investor Relations
  • Ms. Esther Wick, Exec. VP of Legal, IP & Compliance
  • Ms. Valérie Leyldé, Exec. VP of HR & Communications
  • Mr. François Lacoste, Exec. VP of R&D
  • Mr. Mark Miller, Exec. VP & Chief Medical Officer
  • Mr. Pierre Charbonnier, Exec. VP of Global Quality, Manufacturing & Supply Chain

What is bioMérieux's stock symbol?

bioMérieux trades on the OTCMKTS under the ticker symbol "BMXMF."

How do I buy shares of bioMérieux?

Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is bioMérieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $140.26.

How big of a company is bioMérieux?

bioMérieux has a market capitalization of $16.60 billion and generates $3.00 billion in revenue each year. The company earns $305.54 million in net income (profit) each year or $2.58 on an earnings per share basis. bioMérieux employs 12,000 workers across the globe.

What is bioMérieux's official website?

The official website for bioMérieux is www.biomerieux.com.

How can I contact bioMérieux?

bioMérieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.